Neratinib did not show any benefit in the metastatic setting in HER-2-overexpressing breast cancer when compared to lapatinib and capecitabine [39,40], but it was revealed to be effective when in combination with capecitabine [41], warranting its approval in the metastatic setting beyond third line. Here, ERBB2 is linked to breast cancer.